Entering text into the input field will update the search result below

POINT Biopharma Global initiated at buy at Truist on prostate cancer candidate

Sep. 16, 2022 11:09 AM ETPOINT Biopharma Global Inc. (PNT) StockNVS, BAYRY, BAYZFBy: Jonathan Block, SA News Editor

Wall Street sign post in front of Stock Exchange building in New York, USA

ozgurdonmaz

  • Truist has initiated POINT Biopharma Global as a buy citing the potential of PNT2002, its prostate cancer therapy candidate in phase 3.
  • The firm has a $22 price target (~161% upside based on Thursday's close).
  • Analyst Nicole Germino

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
PNT--
POINT Biopharma Global Inc.